Geoffrey Shouse, DO, PhD, discusses what motivated this retrospective review of bispecific antibodies in diffuse large B-cell lymphoma at City of Hope.

These cells make antibodies, which are proteins that ... designed to manage your symptoms and the side effects of treatment. How large B-cell lymphoma may change over time Occasionally, a slow ...

Recent innovations include engineering CAR T-cells to overcome the immunosuppressive tumour microenvironment and enhancing their ability to infiltrate solid tumours.

Incyte and Morphosys’ Monjuvi antibody therapy has been approved for certain ... for adults with relapsed or refractory diffuse large B-cell lymphoma not otherwise specified.

report the results of a phase 2 trial of the CD20–CD3 T cell-engaging bispecific antibody ... diffuse large B cell lymphoma after failing chimeric antigen receptor T cell therapy.

Roche has secured approval from the European Commission (EC) for Columvi (glofitamab) plus gemcitabine and oxaliplatin (GemOx ...

Our immune systems weaken as we get older, making fewer cells that fight infection and help us recover from illness and injury. Scientists aren't completely sure why. They may have a better idea now, ...

Research has shed light on how a new type of antibody treatment reactivates patients' immune cells to fight ovarian cancer.

A novel cell therapy approach using cord blood-derived natural killer (NK) cells pre-complexed with AFM13, or acimtamig, a CD30/CD16A bispecific antibody, was safe and generated strong response rates ...

New research has revealed how a novel IgE antibody (MOv18) therapy reactivates the immune cells of ovarian cancer patients, enabling them to fight the disease more effectively. Conducted by ...